Those venturing into space face a very serious occupational hazard -- cancer. The disease can be caused by radiation from the cosmic rays and solar flares astronauts encounter when they travel beyond the Earth's protective magnetic layer or magnetosphere.

British scientists are working on rectifying this problem by creating a Star Trek-style deflector shield to protect astronauts from radiation.

Think about this:

Scientists wish to mimic the magnetic field that protects the Earth with shields deployed around spacecraft and on the surfaces of planets to deflect harmful energetic particles.

Details, presented at the Royal Astronomical Society's National Astronomy Meeting in Preston, UK, include the following:

• The idea has been linked to the deflector shields that protect the USS Enterprise and other spacecraft on Star Trek. The shields, like on the TV show, could be switched on and off.

• In order to make the shield, scientists must generate a magnetic field and then fill it with ionized gas, or plasma. As energetic particles interact with the plasma, energy is sapped away from them, causing them to slow down.

• Protective shelters would not work on long-duration space journeys due to the drip of energized particles, thought to be as harmful as large solar storms.

"The nice thing is that magnet technology is really quite evolved here on Earth," says Dr. Mike Hapgood, from the Didcot-based research centre. The question is can you take it into space?"

A team from Rutherford-Appleton plans to build an artificial magnetosphere in the laboratory. They would eventually like to fly a test satellite which would test the technology in space.

Is there a link between breast cancer and abortion? This is the first of I've heard of it -- and I consider myself fairly well-versed in the topic of breast cancer. Maybe I missed a beat somewhere along the line.

Think about this:

There is a Coalition on Abortion/Breast Cancer out there and Karen Malec, head of the group, says there would be far fewer breast cancer cases and deaths if women had been told the truth in the 1980s when conclusive evidence linked abortion with the disease.

Malec reports that government scientists wrote a letter in 1986 to the British journal Lancet, acknowledging that abortion causes breast cancer. She says as of 2006, eight medical organizations had recognized abortion as one cause of the disease.

Now this has nothing to do with delaying pregnancy until later in life -- also a known risk factor. Abortion stands on its own and is problematic because carrying a pregnancy to term is what protects against breast cancer, says Malec.

The American Cancer Society (ACS) does not agree and stands behind several studies backed by strong data concluding induced abortions have no overall effect on the risk of breast cancer.

Malec says such studies are seriously flawed.

"We call on the Society and other cancer businesses to put their priorities in order," she says. "Women's lives and cancer prevention are more important than making money, doing cancer walks, and protecting the abortion and pharmaceutical industries."

Malec also condemns Susan G. Komen For the Cure for donating money to Planned Parenthood -- a group she calls the nation's leading abortion business.

"It's unthinkable that groups that claim to want to eradicate the disease would help fund a cancer-causing organization, especially when the funds could be directed to legitimate health organizations."

Unthinkable? I'm not sure.

I need to think about it.

Red meat makes headlines -- again -- due to new research indicating it increases a woman's chances of developing breast cancer. I've heard this before. Maybe that's because it's becoming pretty conclusive.

Findings are most significant for post-menopausal women because these are the women with the highest rates of consumption -- about one portion of red meat per day. This daily doses puts them at a 56 percent greater risk than women who eat no red meat.

Researchers at the University of Leeds followed the eating habits and health of more than 35,000 women over the past seven years to gather their data, published in the British Journal of Cancer.

British researchers have found a connection between inflammatory polyarthritis, rheumatoid arthritis, and cancer. The connection -- a 40 percent increase in cancer mortality in patients with both arthritis conditions.

This is a striking finding, say researchers, whose study is published in the March issue of Arthritis & Rheumatism.

"The results of this study demonstrated that five-year cancer survival in patients with IP is substantially reduced in comparison with that in the general population, even after adjusting for differences in age, sex, and cancer site, whereas the overall cancer incidence does not seem to be increased," says study leader Dr. Alan Silman, an epidemiologist with the University of Manchester.

It's already been established that type 2 diabetes increases the risk of pancreatic cancer. And now, research indicates there is also a link between type 1 diabetes and this type of cancer.

The risk is relatively small -- but still, those with type 1 diabetes have a likelihood of developing pancreatic cancer that is twice as high as in non-diabetics. This is similar to the risk those with type 2 diabetes face.

There are many theories about the link between diabetes and pancreatic cancer, and this research -- published in the British Journal of Cancer -- helps narrow the scope of the theories.

For example, one researcher says the study rules out "a cancer-inducing role of the insulin-producing beta-cells in the pancreas, because in type 1 diabetes these cells have largely or entirely been destroyed."

Experts say people with diabetes should focus their attention on the most common complications of diabetes such as heart disease, eye disease, and kidney disease and not on the very small risk of cancer. In the whole scheme of things, pancreatic cancer is a rare disease -- and even twice the risk is not very significant.

Findings from an international study suggest that women with a waist size of more than 34 inches are more likely to develop cancer of the womb than women who boast slimmer waistlines.

The study, funded in part by the British charity Cancer Research UK, sized up 223,000 women worldwide and determined that women with a waistline less than 31 inches have half the risk of developing womb cancer than their heavier counterparts.

There has been a significant rise in cases of womb cancer in Britain. And the link between the disease and weight gain is most prevalent among postmenopausal women who have never used hormone replacement therapy or the birth control pill.

According to the National Sizing Survey conducted in 2004, the average British woman now has a 34-inch waist. This is more than six inches bigger than the average size of a woman in the 1950s, says Dr. Lesley Walker of Cancer Research UK.

"Women are larger than they were when they existed on a wartime diet and were generally more active and this is having serious consequences," Walker says.

More than 6,000 women in the UK are diagnosed with womb cancer each year. The disease kills about 1,000 annually.

The flu is what caused Australian pop star Kylie Minogue to cut a live London show short on Saturday. Her cancellation had nothing to do with breast cancer, her spokesman says.

Minogue, who was diagnosed with breast cancer in May 2005, has endured both surgery and chemotherapy and is back on the Showgirl Homecoming Tour she had to postpone just after her diagnosis. The revival of her tour represents Minogue's cancer comeback -- and this recent health setback is nothing more than a temporary bout with the flu. It is reported that several of her band members also have the bug.

Minogue, 38, kicked off the British leg of her tour on New Year's Eve. She has already played seven dates at London's Wembley Arena.

This just in from a survey conducted by Cancer Research UK:

More than one in four British adults believe cancer results from nothing more than fate. That's 27 percent of the adult population claiming cancer risk comes down to fate and is not linked to human predisposition or behavior.

Clearly, there are proven cancer-reducing behaviors -- like stopping smoking, maintaining a healthy weight, eating fruits and vegetables, and avoiding the sun -- and the fact that so many adults don't realize that half of all cancer cases can be prevented by lifestyle is alarming.

Dr. Lesley Walker, director of information at Cancer Research UK, says education is key for this group, dominated by British residents living in the most deprived areas of Britain and those over the age of 65.

The breast cancer drug Tykerb may be one of the future wonder drugs available for women left with limited options for treating advanced-stage disease.

Tykerb, manufactured by British-based GlaxoSmithKline PLC, is currently an experimental drug that delays growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin -- a targeted drug that significantly decreases chances of recurrence for women with HER2 positive breast cancer. Herceptin blocks the swift growth of an aggressive protein on the cell's surface while Tykerb does its work on the inside of the cell. Herceptin is given intravenously. Tykerb is given in pill form.

Two previous posts -- one in April and one in June -- relfect the progress of Tykerb as reported in the media. With each new report, Tykerb seems to gain momentum and promise. And this past week, new reports revealed new promise as Glaxo began seeking regulatory approval of the Tykerb pill in Europe.

Glaxo has filed an application with the Food and Drug Administration for approval of this drug and is preparing to market the drug for the treatment of advanced breast cancer in women. Glaxo hopes to launch Tykerb -- also known as lapatinib ditosylate -- next year.

The UK's Cancer Research All Join Together Campaign will sell pink and white rubber ducks for breast cancer awareness month. The rubber duck will raise funds and also come with information on being breast aware.

Lesley Walker, director of cancer information at Cancer Research UK, explains "Relaxing in the bath is an ideal time for women to notice any abnormal change in either breast. It is very important for women to know what is normal for them and bath time is a great time to look for any changes"

Five British women, who are survivors of breast cancer, are portrayed in the campaign that will be displayed in over 600 Cancer Research UK shops nationwide throughout breast cancer awareness month.

Rub a dub dub....

Billionaire Dutch businessman, philanthropist, outspoken environmentalist and wildlife conservationist Paul Fentener van Vlissingen, who owned the 81,000-acre Letterewe Estate in Scotland, as well as nature reserves in England and wetland reserves in the Netherlands, and who founded the Africa Parks Foundation (APF) developing parks in Malawi, Zambia and Ethiopia, has lost his life to pancreatic cancer.

Paul van Vlissingen and the van Vlissingen family are well-known in the Netherlands for the many generations of interest and efforts on behalf of wildlife. He was said to be involved in environmental causes on every continent. To promote responsible management of nature, he appeared in television programs with Prince Charles. In addition, he was a published author and spoke publicly on environmental causes.

A few excerpts from his obituary read:

"He supported human population control, but believed it could be attained only through choice and empowering women through education and equality."

Noting how as a boy Van Vlissingen spent much of his time outdoors, reading voraciously and writing poetry, his parents joked: "We have three children and a gypsy."

"He was convinced that continual change is the oxygen a company needs for its survival. He was also convinced that both fun and challenges in the working environment were important for all, and he evolved a managerial style which emphasized respect for, and investment in, people."

When Van Vlissingen was diagnosed with cancer, he founded the Van Vlissingen Cancer Fund in the Netherlands. Paul Fentener van Vlissingen was 65. Fascinating man.

John Diamond was a British journalist who died from tongue cancer in 2001. He wrote a book called Because Cowards Get Cancer Too: A Hypochondriac Confronts his Nemesis.

This book is different than your normal cancer read. I say that because of John Diamond's wit and intelligence when writing about his cancer experience. His sarcasm when it came to things like people telling him that he was brave was right on. He didn't think he was brave for going through cancer treatments, he thought that it was his only choice, something he had to do. This book is a realistic look at things that were going on around him and within him. John, you and I are definitely on the same page!

I have already read this book twice and when I find it I'm going to read it again.

Regaining focus after losing a loved one to cancer is a tough thing for anyone. Last month Professional golfer Tiger Woods missed his first ever cut in a major championship at the US Open following the loss of his father Earl Woods to prostate cancer on May 3. Tiger regained his focus one month later to win the British Open today.

Mourning for someone you have cared for and loved is a necessary part of feeling better again and continuing with your own life. You will often experience emotions of intense sadness and despair, or it may be hard to believe that the person has really died. You may feel that crying is a sign of weakness, or that you are falling apart but grieving is the way we begin to heal ourselves, just as an injury needs time to heal.

With an emotional breakdown of tears on the finishing hole, Tiger Woods wept openly in the arms of his caddy Steve Williams. This was his first victory since his father's death and some critics questioned whether Woods could regain the focus needed to stay on top of the rankings in the professional golf world. Watching the British Open on television and seeing the final shot by Tiger filled my eyes with tears to know the pain this man felt while winning such a glorious title in golf without the presence of the father that has stood by him his whole career. But he regained his stance at the top of the world rankings and keeps the focus that was taught to him by his father Earl Woods.

"After the last putt, I realized my dad's never going to see this again, and I wish he could have seen this one last time," Woods said at the trophy presentation. "He was out there today keeping me calm. I had a very calm feeling the entire week, especially today."

Tiger Woods now has three British Open titles, the same as Jack Nicklaus, and his victory at Hoylake carried another comparison. The first major Nicklaus won after his father died in 1970 also was the British Open.

Someone once told me to think of cancer as a chronic condition -- an illness like diabetes or asthma that may linger for life and may require continual treatment. And while battling cancer, perhaps for life, I should just hope that medical advances occur and new treatments become available. And maybe, just maybe, the science of medicine will decrease by leaps and bounds the number of people who die from cancer.

During my own battle with cancer -- which has been 18 months long -- two new breast cancer drugs have hit the scene with rave reviews from researchers and medical professionals. This is good news for me because my type of breast cancer makes me a candidate for both drugs. Herceptin is one of these drugs -- given to women who are HER-2/neu positive -- that's me -- and over express a protein that makes the tumor aggressive. Herceptin is received over 52 weeks -- and I go every three weeks for a 90-minute infusion of this clear liquid that causes me really no side effects at all. It can be toxic to the heart but monitoring tests have revealed that my heart is not suffering at this time. And with just three more infusions to go -- one this Wednesday -- I will likely encounter no adverse reactions to this potentially life-saving drug.

And now Tykerb is making headlines. Tykerb, suggested for use with advanced breast cancer and manufactured by British-based GlaxoSmithKline PLC, is an experimental drug that delays the growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin. This finding, reported this past Saturday at a meeting in Atlanta of the American Society of Clinical Oncology, confirms initial findings about the promise of this drug -- that like Herceptin, made by Genentech, precisely targets tumors without killing lots of healthy cells. The difference between the two drugs is that Herceptin blocks the protein on the cell's surface and Tykerb does it inside the cell -- blocking a second abnormal protein too. And while Herceptin is given intravenously, Tykerb is given in pill form -- which may make it cheaper and easier to use.

While now part of an international study, Tykerb may be available to women in the United States later this year. And it perhaps will be offered in conjunction with Herceptin or instead of Herceptin for women with advanced breast cancer.

I hope I do not ever need Tykerb -- and that Herceptin alone will be enough for me -- but it is comforting to know that there is something else out there. Something that if necessary, just might help me live with this potentially chronic condition called cancer.